• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Alcon EDOF IOL reaches 1 million milestone


According to the company, the milestone underscores Vivity’s wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients.

(Image credit:AdobeStock/hobbitfoot)

(Image credit:AdobeStock/hobbitfoot)

Alcon announced the AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) intraocular lenses (IOLs) have surpassed more than 1 million implants worldwide. Vivity is the most implanted EDOF IOL globally.1

Sean Clark, president, Global Surgical Franchise at Alcon, said in a news release the company was pleased to mark the 1 million Vivity eyes empowering cataract patients to see the world with high quality vision from distance to functional near—day and night.

“This milestone embodies our commitment to addressing the diverse vision needs of today's patients, who desire less dependence on glasses post-surgery and low visual disturbances, with a game-changing presbyopia-correcting intraocular lens (PCIOL) option that expands the patient candidacy pool,” he said in a statement.

According to the company, Vivity uses Alcon’s patented non-diffractive Wavefront-Shaping X-WAVEtechnology, an optical principle that simultaneously stretches and shifts light without splitting it—balancing quality of vision and maximizing range of vision.2,3

The optic delivers distance and intermediate vision, as well as functional near vision.2 The mechanism of action is not refractive, does not introduce spherical aberrations and has ultimately expanded PCIOL access to even more patients. Vivity is designed to simplify presbyopia correction, prioritizing patient satisfaction while minimizing surgeon and clinic chair time.

Recent, large-scale real-world data underscores the impact of Vivity on patients across the globe. The Vivity Registry Study4 includes patients with common mild comorbidities like glaucoma, dry eye and retinopathy/maculopathy, as well as post-refractive eyes. The Registry data demonstrates high patient satisfaction among several patient cohorts, as the vast majority of patients (92%) report they are satisfied with their sight. Additionally, more than 91% of patients report no haloes, glares, or starbursts.†

Vivity is available in more than 80 countries, including Australia, Brazil, Canada, China, France, Germany, Japan, India, Italy, Russia, South Korea, Spain, U.K. and the United States. Alcon offers a family of IOLs designed to meet the vision needs of patients, including Vivity and PanOptix—as well as monofocal and toricoptions. PanOptix surpassed one million implants in early 2022, and is the most implanted trifocal worldwide.5,6

The non-diffractive Clareon Vivity extended vision hydrophobic posterior chamber IOLs (referred to as Clareon Vivity) and AcrySof IQ Vivity extended vision posterior chamber intraocular lens Model DFT015 (referred to as AcrySof IQ Vivity IOL) are UV-absorbing and blue-light-filtering foldable intraocular lenses (IOLs). Vivity® IOL provides an extended range of vision from distance to near, with low levels of visual disturbances.

The AcrySof IQ PanOptix Trifocal IOL and the Clareon PanOptix Trifocal IOL are types of multifocal IOLs used to focus images clearly onto the back of the eye (retina) to allow clear vision after the cataract removal. In addition, the center of the PanOptix Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide.

  1. Market Scope - 2023 Premium Cataract Surgery Market Report; 2023 IOL Market Report.
  2. Alcon Data on File; U.S. Pat. Nos. RE45,969, 9,968,440, 11,083,566.
  3. AcrySof® IQ Vivity® or Clareon® Vivity® IOL Directions for Use.
  4. Reus NJ, Kooijman M, Perez-Vives C. Overall Visual Outcomes from a Real-world Study of Presbyopia-correcting IOLs in a Large Population. Presented at the European Society of Cataract and Refractive Surgery (ESCRS) Annual Meeting; 8-12 Sept. 2023; Vienna, Austria.
  5. Alcon IOL Global Sales; Jan. 2021-Nov. 2022.
Related Videos
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
© 2024 MJH Life Sciences

All rights reserved.